CLASSIFICATION: Applied and Environmental Science, Microbiology

Title: Antibiotic Resistance in *Bacillus*-based Biopesticide Products

Running Title: Antibiotic Resistance in Biopesticides

AUTHORS: Mo Kaze^{A#}, Lauren Brooks^B, Mark Sistrom^A

A) Department of Quantitative and Systems Biology, School of Natural Sciences, University of California Merced, USA

B) Department of Biology, Utah Valley University, USA

Corresponding author

Mo Kaze

UC Merced

5200 N Lake Rd

Merced, CA 95343

mkaze@ucmerced.edu

(415) 699-5255

KEYWORDS: Antibiotic Resistance, Genomics, *Bacillus*, Biopesticides

Abstract

The crisis of antibiotic resistant bacterial infections is one of the most pressing public health issues. Common agricultural practices have been implicated in the generation of antibiotic resistant bacteria. Biopesticides, live bacteria used for pest control, are non-pathogenic and considered safe for consumption. Application of bacteria-based pesticides to crops in high concentrations raises the possibility of unintentional contributions to the movement and generation of antibiotic resistance genes in the environment. However, the presence of clinically relevant antibiotic resistance genes and their resistance phenotypes are currently unknown. Here we use a combination of multiple bioinformatic and microbiological techniques to define resistomes of widely used biopesticides and determine how the presence of suspected antibiotic resistance genes translates to observable resistance phenotypes in several biopesticide products. Our results demonstrate that biopesticide products are reservoirs of clinically relevant antibiotic resistance genes and bear resistance to multiple drug classes.

Importance

This is the first study to specifically address antibiotic resistance in widely distributed bacterial strains used as commercial biopesticides. Safety assessments of commercial live bacterial biopesticide products do not include antibiotic resistance phenotype identification. We identify antibiotic resistance genes in all live bacterial strains examined, and resistant phenotypes in all strains tested for antibiotic susceptibility. This work demonstrates that biopesticides potentially play a critical role as reservoirs and vectors of antibiotic resistance in the broader environmental resistome that is to date, unstudied.

Introduction

The increasing prevalence of antibiotic resistant bacterial infections is one of the most pressing public health crises of the current era. Without significant efforts to curb antibiotic resistant infections, 10 million human deaths per annum are estimated to occur by 2050 along with severe impacts to animal husbandry and subsequent food production.(1-2) A large body of research has investigated the spread of antibiotic resistance via common agricultural practices, implicating many in the generation of antibiotic resistant bacteria.(1-6) The widespread use and presence of antibiotic compounds in the broader environment, and the ubiquitous presence of genes encoding resistance to them, play a critical role in the evolutionary mechanisms affecting antibiotic resistance. Clinically relevant and nonclinical bacterial species residing in microorganismal communities horizontally transfer resistance genes. These exchanges subsequently influence the prevalence and patterns of antibiotic resistant infections.(7,8)

The use of microorganisms in agriculture for pest control, frost prevention, and rhizosphere enhancements has steadily increased over the last 20 years.(9,10) Considered safe for consumption, non-toxic, non-pathogenic and highly effective,(11–14) microbial products offer a welcome alternative to chemically synthesized pesticides known to cause damage to human health and the environment.(15, 16) Microbes used as biopesticides are classified “Generally recognized as safe” (GRAS) by the US FDA(17) as they do not pose a threat to human health. However, these microorganisms have the potential to contribute to the pervasiveness of antibiotic resistance through genes encoded in bacterial genomes and mobile genetic elements. It is crucial to identify clinically relevant antibiotic resistance genes present in live bacterial biopesticides used in large scale applications to prevent unintentional contributions to the spread of antibiotic resistance genes and the expansion of antibiotic resistance gene reservoirs. There is an urgent need to understand the role biopesticides play in the transmission of antibiotic resistance genes and their roles as potential vectors.

Bacillus-based biopesticides are increasingly popular. *Bacillus thuringiensis* (Bt) is the most widely used biopesticide in industrial agriculture. Aerial Bt spraying has replaced aerial DDT, a known environmental toxin, for control of moths, blackflies, mosquitoes, and many other pests in forestry, agriculture, and urban areas.(18,19) Out of commercial *Bacillus*-based biopesticides, Bt is considered the safest, and has been in use globally for more than 80 years.(20) Bt is a Gram positive, aerobic, soil-dwelling bacteria characterized by the presence of plasmids containing *cry* and *cyt* genes.(21) These two toxin genes and their variations confer unique insecticidal properties. Bt is genetically plastic and has special capability regarding plasmid acceptance and maintenance. This biopesticide species has previously been shown to host as many as seventeen plasmids.(22)

This study represents the first effort to assess the potential role of live, commercial bacterial biopesticides as reservoirs of antibiotic resistance genes, and to connect antibiotic resistance phenotypes to resistance genotypes. We analyze four commercially available *Bacillus*-based biopesticide strains: two Bt kurstaki products, *B. amyloliquefaciens* D747, and *B. subtilis* QST 713, using a combination of bioinformatics and antibiotic susceptibility testing. We classify all antibiotic resistance genes in these *Bacillus*-based biopesticide products by comparing whole-genome sequenced products against the Comprehensive Antibiotic Resistance Database (CARD) and annotating sequenced genomes.(23) This work demonstrates that currently used commercial *Bacillus*-based biopesticides contain clinically relevant antibiotic resistance genes and bear resistance to multiple drug classes. These findings raise concern regarding potential vectors of unintended transmission of antibiotic resistance as they are introduced to the environment in large quantities.

Methods

A list of all *Bacillus*-based biopesticide species approved for use in the US was collated from databases published by the California Department of Pesticide Registration and United States Environmental Protection Agency databases.(24) In order to narrow down antibiotic selection, publicly available complete, whole reference genomes matching strain information were queried against the Comprehensive Antibiotic Resistance Database v3.0 (downloaded November 2019) using Blastn 2.10.0(25) with default settings, except for a 97% cut off for query coverage and 97% percent for percent identity match. Reference genome annotations were manually reviewed for antibiotic resistance genes and proteins. Drug classes that were not present in the reference genomes were not included for phenotype testing.

Four commercial *Bacillus*-based biopesticide products, Bt subspecies kurstaki strain SA12, *B. subtilis* strain QST 713 and *B. amyloliquefaciens* strain D747, were purchased and named: Bt-kurstaki-1, Bt-kurstaki-2, *B. subtilis*, and *B. amyloliquefaciens*. The two Bt products were the same strain, but from different companies and contained different suspension materials. Commercial biopesticide products were cultured using standard methods and McFarland turbidity as specified in the American Society of Microbiology Kirby-Bauer Disk Diffusion Susceptibility Test Protocol(26) and assayed with Oxoid (Thermo Fisher, USA) antimicrobial susceptibility disks for clindamycin (2 µg), doxycycline (30 µg), linezolid (30 µg), sulfamethoxazole/trimethoprim (25 µg), and vancomycin (30 µg). Minimum inhibitory concentration (MIC) was determined using the standard Clinical and Laboratory Standards Institute guidelines(27) on replicates using Liofilchem (Liofilchem Inc. MA) antibiotic minimum inhibitory concentration test strips and aerobe incubation protocols for cephazolin (0.016 – 256 µg/mL), clindamycin (0.016 – 256 µg/mL), ceftazidime (0.016 – 256 µg/mL),

quinupristin/dalfopristin (0.002 – 32 µg/mL), ertapenem (0.002 – 32 µg/mL), imipenem (0.002 – 32 µg/mL), erythromycin (0.016 – 256 µg/mL), and tetracycline (0.016 – 256 µg/mL) antibiotics. MIC breakpoints were obtained from EUCAST.(28)

DNA from biopesticide products was extracted directly and from Luria-Bertani cultures using Qiagen's DNeasy DNA Extraction kit (Qiagen NV, Germany) with a modified protocol. After performing the protocol's first step, samples were incubated at 90°C for 10-15 minutes in order to account for Gram positive cell wall structure. DNA concentration was quantified using a Qubit fluorometer (Thermo Fisher Scientific, MA) and quality and purity quantified using an Eppendorf Biospec (Eppendorf, Germany). Libraries were generated using Illumina NextTera Flex kit with IDT set A Dual Indexes. DNA was sequenced on an Illumina MiSeq platform (Illumina Inc, CA). Sequences were checked for quality using FastQC v0.11.8(29) and trimmed using Trimmomatic v0.36. (30) Genomes were assembled using SPAdes v3.11.1.2(31) and assessed for quality using Quast v5.0.0.(32) Genomes were annotated with RAST v4.0.2(33) and assemblies were queried against CARD and manually curated for antibiotic resistance annotations and verified against UniProt. (34) Annotated and CARD-identified antibiotic resistance genes were quantified in R Studio v 1.4.1103.(35)

Results

Antibiotic Susceptibility

Each biopesticide product demonstrated antibiotic resistance phenotypes to the clinically relevant antibiotics tested. (**Table 1**) The MIC range for replicates for clindamycin was 0.064 µg/mL to 0.19 µg/mL and erythromycin was 0.125 µg/mL to 0.19 µg/mL. Ertapenem resistance for all products ranged from 0.125 µg/mL to 0.19 µg/mL. Imipenem resistance was observed in Bt-kurstaki-1, Bt-kurstaki-2 and *B. amyloliquefaciens* products. Bt-kurstaki-1 was interpreted as

resistant with all replicates measuring 1.5 µg/mL. Bt-kurstaki-2 was resistant in 20% of replicates (sd. 1.6) and 80% were susceptible to imipenem and ranged from 0.094 µg/mL to 4.0 µg/mL. *B. amyloliquefaciens* was susceptible to imipenem in 80% of replicates and ranged from 0.032 µg/mL to 0.75 µg/mL (sd. 0.3). Resistance to quinpristin/dalfopristin was observed in *B. amyloliquefaciens* measuring 3.0 to 4.0 µg/mL (sd. 0.3) and *B. subtilis* measuring 3.0 µg/mL. Both of these biopesticide products were also resistant to tetracycline. Bt-kurstaki-1 and Bt-kurstaki-2 had complete resistance to both cephalosporins tested, ceftazidime and cefazolin, with MICs of 256 µg/mL. Disk diffusion assays showed resistance to two of the five antibiotics tested. (**Table 2**) Clindamycin resistance was observed in 25% of Bt-kurstaki-1 (n = 12, 0 mm). Sulfamethoxazole/trimethoprim resistance was observed in 33% of Bt-kurstaki-2 replicates (n = 9, 10 mm). *B. subtilis* and *B. amyloliquefaciens* were susceptible to all five antibiotics. All four biopesticide products tested were susceptible to doxycycline, linezolid, and vancomycin. Resistance to five total drug classes, across the four biopesticide products, was observed: cephalosporins, lincosamides, streptogramins, sulfonamides, and tetracyclines. (**Fig. S1, Fig.S2**)

Molecular Characterization

Genotypes for each biopesticide product contained multiple antibiotic resistance genes for the five drug classes of the observed resistance phenotypes. Both methods used to identify antibiotic resistance genes, a curated database of resistance genes and genome annotation, identified antibiotic resistance genes associated with the nine tested drug classes. For the five drug classes represented by the resistance phenotypes, CARD identified twelve genes and genome annotation identified seven. Of the fifty-two total antibiotic resistance genes identified

by CARD and the forty-seven identified by genome annotation, less than half resulted in an expressed resistance phenotype (44% and 47% respectively).

CARD identified twenty-two antibiotic resistance genes associated with the antibiotics tested for susceptibility. (**Fig. 1a**) *Bt-kurstaki-1* had eighteen (82% of the total genes for the nine tested drug classes) genes for resistance to eight drug classes: carbapenems (Bla2, MexB, MexY), cephalosporins (BcI, BcII, lsaB, MexB, MexD, MexY), glycopeptides (vanRM), lincosamides (lsaB), macrolides (lsB, mdtF, MexB, MexD, MexY), oxazolidinones (lsaB), sulfonamides (MexB, sul1), and tetracyclines (acrA, lsaB, MexB, MexD, MexY, MuxB, MuxC, oqxA, oqxB, smeE, tet(L)). *Bt-kurstaki-2* had six genes for seven of the drug classes tested: carbapenems (Bla2), cephalosporins (BcI, BcII, lsaB), glycopeptides (vamRM), lincosamides (lsaB), macrolides (lsaB), oxazolidinones (lsaB), and tetracyclines (acrA, lsaB). *B.*

amyloliquefaciens and *B. subtilis* products contained the same five genes associated with six of the tested drug classes: cephalosporins (hns), lincosamides (cfr(B), clbA, clcD), macrolides (hns), oxazolidinones (cfr(B), clbA, clcD), streptogramins (cfr(B), clbA, clcD), and tetracyclines (hns, tet(L)).

Gene annotation of sequenced biopesticide genomes identified twenty-two genes associated with the antibiotics tested for susceptibility. *Bt-kurstaki-1* and *B. subtilis* contained all twenty-two genes for eight drug classes. *Bt-kurstaki-2* contained fourteen (67%) genes which were associated with six drug classes: cephalosporins (AcrE, CmeABC, MarA, MarB, MarR), carbapenems (MarA, MarB, TolC), lincosamides (ErmA, ErmB), macrolides (CmeABC, ErmA, ErmB), streptogramins (ErmA, ErmB), and tetracyclines (AcrA, MarA, MarB, MarR, mdfA, tetR, TolC). *B. amyloliquefaciens* had nineteen (86%) genes associated with eight of the tested drug classes: carbapenems (MarA, MarB, TolC), cephalosporins (AcrE, CmeABC, MarA, MarB,

MarR), erythromycins (mdlB), glycopeptides (vanW), lincosamides (ErmA, ErmB), macrolides (CmeABC, ErmA, ErmB, MacA, MacB, TolC), streptogramins (ErmA, ErmB), and tetracyclines (AcrA, MarA, MarB, MarR, MdfA, tetR, TolC, YkkC, YkkD). The complete list of identified antibiotic resistance genes are summarized in **Table 3**.

The two methods used to determine genotypes provided different results and neither method accounted for differing genotypes relating to drug class phenotype. Annotation did not identify genes for oxazolidinone and sulfonamide resistance. Seven resistance genes were identified by both methods: AcrA, Bla1, CpxA, fosB, MdtB, MdtC, and TolC. Annotation identified the majority of the genes associated with the antibiotic phenotypes observed. CARD identified twenty-one drug classes total and genome annotation identified fourteen drug classes. Comparing the two products with identical strains, eighteen genes were identified by CARD for Bt-kurstaki-1 and six in Bt-kurstaki-2, whereas annotation identified twenty-two genes in Bt-kurstaki-1 and fourteen in Bt-kurstaki-2. The quantification of total genes identified by both methods showed little variation between the two. (**Fig. S3**)

Discussion

Agricultural practices currently implicated in the antibiotic resistance crisis do not currently encompass all processes contributing to the spread and maintenance of resistant bacteria in the environment. Biopesticides are disseminated globally in large quantities but have yet to be looked into as reservoirs of antibiotic resistance genes resulting in a lack of data regarding biopesticide-specific strains' resistance phenotypes and accounting of their resistance genotypes. Assessing antibiotic resistance phenotypes or genotypes has not historically been included when testing the safety of biopesticide use or included in antibiotic resistance

surveillance. Biopesticide products may act as latent carriers and as potential vectors of resistance to human pathogens which may not be determined by susceptibility testing of biopesticide products. This study spotlights antibiotic resistance phenotypes and genotypes in *Bacillus*-based biopesticides and signals the need for investigation of this agricultural practice acting as reservoirs of antibiotic resistance along the food chain.

Bacillus-based biopesticide strains harboring a variety of antibiotic resistance genes and expressing resistance to first-generation antibiotics, such as narrow spectrum beta-lactamases, is expected. However, resistance phenotypes and genotypes associated with later generation, clinically important antibiotics is cause for serious concern. The addition of large amounts of live bacteria for pest control increases the likelihood of horizontal gene exchange between pathogenic bacteria and biopesticides bearing resistance genotypes. All assayed biopesticide products demonstrated resistance phenotypes to two clinically important antibiotics. We observed resistance to five drug classes, all designated critically important by the World Health Organization: cephalosporins, carbapenems, lincosamides, streptogramins, and tetracyclines. (36) Genotypes contain genes capable of conferring resistance to additional clinically relevant antibiotics and biocides. Both *B. thuringiensis* products demonstrated complete resistance to ceftazidime, a third-generation cephalosporin. Resistance to third-generation broad spectrum cephalosporins are of special concern, the WHO has categorized this drug class as “highest priority critically important antimicrobials.”(26) Resistance to imipenem, a broad spectrum beta lactamase usually reserved for multi-drug resistant infections,(37) was found in one *B. thuringiensis* product, and in some replicates of the other *B. thuringiensis* product, as well as in *B. amyloliquefaciens* replicates.

There are previous examples of studies identifying antibiotic resistance phenotypes and genotypes in additional biopesticide genera. (38) Patel et al. identified vancomycin resistance clusters in biopesticide *Paenibacillus popillae*. (39) *Burkholderia ambifaria*, while no longer approved for biopesticide use in the United States, (40) contains genes required for resistance-nodulation-cell division (RND) efflux pumps.(40) We identified accessory genes associated with vancomycin resistance in the assayed biopesticide products, vanRM (CARD) vanW and vanZ (annotation). While the role of these genes is not currently understood, (39,42) the lack of other essential components likely explains why vancomycin resistance was not observed in any product. Luna et. al. tested six *Bacillus* species, both clinical and environmental, for antibiotic sensitivity and observed susceptibility in 100% of *B. thuringiensis* replicates to erythromycin, and vancomycin and 95% of replicates were susceptible to clindamycin and sulfamethoxazole/trimethoprim. (43) These results are similar to our resistance observations for both antibiotics tested against two *B. thuringiensis* kurstaki products. Turnbull et al. tested clinical and environmental isolates of *B. thuringiensis* and identified resistance phenotypes with MICs; 100% of isolates were resistant to cefotaxime, and 80% of isolates were resistant to tetracycline; with all susceptible to erythromycin and vancomycin. (44) Both *B. thuringiensis* kurstaki products we tested demonstrated complete resistance to ceftazidime, a third-generation cephalosporin. Turnbull et. al. isolates were resistant to 3rd generation cephalosporin cefotaxime. (41) While this study was not testing biopesticide specific strains, this report is also consistent with our findings.

Resistance interpretations were determined by comparing results to EUCAST references. (28) However, breakpoints for each species of *Bacillus*-based biopesticide are not available for the majority of clinical antibiotics. When reference values were unavailable interpretations were

determined by comparisons to reference values for related pathogenic *Bacillus*-species and taking into account the strength of the antibiotic dose. Defining resistance phenotypes and genotypes can readily be expanded to include more biopesticide products and additional clinically relevant antibiotics. Genes identified by both methods point to multiple drug classes that require further investigation: *cpxA*, *mtdB*, *mdtC* (aminocourmarins), *Bla1* (penams), *fosB* (fosfomycins), and *arcA*, *TolC* (triclosan). Characterizing the genomes of these products offers an opportunity to define breakpoints for non-pathogenic species and test for additional antibiotic resistance.

Despite vociferous support for *B. thuringiensis* as the “safest ... microbial insecticide available to humanity,” (45) antibiotic resistance phenotypes for critically important drug classes and the potential to share resistance conferring genes via horizontal gene transfer have not been included in any safety assessment. We observed individual mechanism genes for incomplete RND efflux pumps, e.g., CARD identified only *smeE*, a member of the complex for a multidrug RND efflux pump (46) as well as *muxB* and *muxC* which require genes *muxA* and *OpmB* to function. (47) *TolC* was identified by both methods, in all four biopesticide genomes. This gene is an essential component of multiple antibiotic resistance gene families: ATP-binding cassette, major facilitator superfamily, and RND antibiotic efflux pumps. (48) While inactive on their own, genetic exchange between strains may generate additional phenotypes as individual genes combine to form functional resistance mechanisms before application. Plasmids have been found to have very large host ranges and genetically plastic *Bacillus* species are able to host many plasmids. (49) Multiple genes identified in the biopesticides tested were initially found in mobile genetic elements: *clbA* is a *cfr* gene found in *B. amyloliquefaciens* subsp. *plantarum* plasmids (50) and *sul1*, confers sulfonamide resistance, is associated with integrons. (4, 51) It is likely that

live bacterial biopesticides come into contact with, and exchange with, other genetically plastic, agriculture associated, antibiotic resistant pathogens such as *Klebsiella pneumoniae* or *Escherichia coli*.(4, 52) TolC has been associated with resistance to fifteen drug classes and has been identified in resistant *K. pneumoniae* and *E. coli*.(53, 54) Including additional methods for genotype characterization, such as use of additional curated databases,(55) may assist in predicting potential vector activity before combining biopesticides. As biopesticides are commonly used in multi-strain consortia it will be important to experimentally determine the capability for exchange between the biopesticides themselves and exchange with agriculturally associated pathogens.

Production of *B. thuringiensis* strains for pest control without creating resistance to broad spectrum antibiotics was proposed as early as 1997, (56) indicating prior concern regarding application of biopesticides acting as antibiotic resistance gene reservoirs. Despite this initial concern, the assertions of a large number of studies regarding the safety of live bacterial pesticides, specifically *B. thuringiensis* strains, mention antibiotic resistance as a factor in their evaluations.(11-14, 19, 20) Anthropogenic input of resistant bacteria in proximity to the largest users of antibiotic compounds has the potential to be a major driver in the increased prevalence of clinically relevant antibiotic resistance genes. To date, this agricultural activity, remains largely uninvestigated. Globally, live bacterial biopesticide products play an essential role in replacing toxic, chemically synthesized pesticides and offer an inexpensive and effective method of pest control. However, our results show the potential of biopesticides as a large reservoir for the generation and dissemination of antibiotic resistance genes on a global scale. While biopesticides have a role in providing safe food production, we have demonstrated that they also may play a role in the antibiotic resistance crisis. We anticipate the role of biopesticides acting

300 reservoirs and vectors of clinically relevant antibiotic resistance genes to become part of the
301 continued research regarding agricultural practices and the generation and spread of antibiotic
302 resistance in the environment. Globally, live bacterial biopesticide products play an important
303 role in replacing toxic, chemically synthesized pesticides and offer an inexpensive and effective
304 method of pest control. However, our results show the potential of biopesticides as a large
305 reservoir for the generation and dissemination of antibiotic resistance genes on a global scale.
306 While biopesticides play an important role in providing safe food production, we have
307 demonstrated that they also maybe play an important role in the antibiotic resistance crisis.

References

1. Center for Disease Control, 2019. Antibiotic Resistance Threats in the United States 2019. US Health and Human Services, Atlanta, GA, USA.
2. Aslam, B., Wang, W., Arshad, M.I., Khurshid, M., Muzammil, S., Rasool, M.H., Nisar, M.A., Alvi, R.F., Aslam, M.A., Qamar, M.U. and Salamat, M.K.F., 2018. Antibiotic resistance: a rundown of a global crisis. *Infection and drug resistance*, 11, p.1645.
3. Schwarz, S., Fessler, A.T., Loncaric, I., Wu, C., Kadlec, K., Wang, Y. and Shen, J., 2018. Antimicrobial resistance among staphylococci of animal origin. *Antimicrobial Resistance in Bacteria from Livestock and Companion Animals*, pp.127-157.
4. Jechalke, S., Heuer, H., Siemens, J., Amelung, W. and Smalla, K., 2014. Fate and effects of veterinary antibiotics in soil. *Trends in microbiology*, 22(9), pp.536-545.
5. Munk, P., Knudsen, B.E., Lukjancenko, O., Duarte, A.S.R., Van Gompel, L., Luiken, R.E., Smit, L.A., Schmitt, H., Garcia, A.D., Hansen, R.B. and Petersen, T.N., 2018. Abundance and diversity of the faecal resistome in slaughter pigs and broilers in nine European countries. *Nature microbiology*, 3(8), pp.898-908.
6. Khachatourians, G.G., 1998. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. *Cmaj*, 159(9), pp.1129-1136.
7. Hernando-Amado, S., Coque, T.M., Baquero, F. and Martínez, J.L., 2019. Defining and combating antibiotic resistance from One Health and Global Health perspectives. *Nature Microbiology*, 4(9), pp.1432-1442.
8. Food and Drug Administration, 2015. Antimicrobials sold or distributed for use in food-producing animals. *US Food and Drug Administration: Silver Spring, MD, USA*.
9. Anderson, J.A., Staley, J., Challender, M. and Heuton, J., 2018. Safety of *Pseudomonas chlororaphis* as a gene source for genetically modified crops. *Transgenic research*, 27(1), pp.103-113.
10. Parnell, J.J., Berka, R., Young, H.A., Sturino, J.M., Kang, Y., Barnhart, D.M. and DiLeo, M.V., 2016. From the lab to the farm: an industrial perspective of plant beneficial microorganisms. *Frontiers in plant science*, 7, p.1110.
11. EFSA Panel on Biological Hazards (BIOHAZ), 2016. Risks for public health related to the presence of *Bacillus cereus* and other *Bacillus* spp. including *Bacillus thuringiensis* in foodstuffs. *EFSA Journal*, 14(7), p.e04524.
12. Roh, J.Y., Choi, J.Y., Li, M.S., Jin, B.R. and Je, Y.H., 2007. *Bacillus thuringiensis* as a specific, safe, and effective tool for insect pest control. *Journal of microbiology and biotechnology*, 17(4), pp.547-559.

13. Federici, B.A. and Siegel, J.P., 2008. Safety assessment of *Bacillus thuringiensis* and Bt crops used in insect control. *Food Science and Technology-New York-Marcel Dekker-*, 172, p.45.
14. Siegel, J.P., 2001. The mammalian safety of *Bacillus thuringiensis*-based insecticides. *Journal of invertebrate pathology*, 77(1), pp.13-21.
15. Nicolopoulou-Stamati, P., Maipas, S., Kotampasi, C., Stamatis, P. and Hens, L., 2016. Chemical pesticides and human health: the urgent need for a new concept in agriculture. *Frontiers in public health*, 4, p.148.
16. Hernández, A.F., Parrón, T., Tsatsakis, A.M., Requena, M., Alarcón, R. and López-Guarnido, O., 2013. Toxic effects of pesticide mixtures at a molecular level: their relevance to human health. *Toxicology*, 307, pp.136-145.
17. Food and Drug Administration, 2016. *Substances Generally Recognized as Safe*. vol. 81 .*US Food and Drug Administration: Silver Spring, MD, USA*.
18. Van den Berg, H., 2009. Global status of DDT and its alternatives for use in vector control to prevent disease. *Environmental health perspectives*, 117(11), pp.1656-1663.
19. Smitley, D.R. and Davis, T.W., 1993. Aerial application of *Bacillus thuringiensis* for suppression of gypsy moth (Lepidoptera: Lymantriidae) in *Populus-Quercus* forests. *Journal of economic entomology*, 86(4), pp.1178-1184.
20. Bravo, A., Likitvivatanavong, S., Gill, S.S. and Soberón, M., 2011. *Bacillus thuringiensis*: a story of a successful bioinsecticide. *Insect biochemistry and molecular biology*, 41(7), pp.423-431.
21. Höfte, H. and Whiteley, H.R., 1989. Insecticidal crystal proteins of *Bacillus thuringiensis*. *Microbiology and Molecular Biology Reviews*, 53(2), pp.242-255.
22. Reyes-Ramírez, A. and Ibarra, J.E., 2008. Plasmid patterns of *Bacillus thuringiensis* type strains. *Applied and Environmental Microbiology*, 74(1), pp.125-129.
23. Jia, B., Raphenya, A.R., Alcock, B., Waglechner, N., Guo, P., Tsang, K.K., Lago, B.A., Dave, B.M., Pereira, S., Sharma, A.N. and Doshi, S., 2016. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic acids research*, p.gkw1004.
24. California Department of Pesticide Regulation, 2018. Summary of Pesticide Use Report Data-2019.
25. NCBI. National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2019] – [cited 2019 Jan 20]. Available from: <https://www.ncbi.nlm.nih.gov/>. (2019).
26. Hudzicki, J., 2009. Kirby-Bauer disk diffusion susceptibility test protocol.

27. Humphries, R.M., Ambler, J., Mitchell, S.L., Castanheira, M., Dingle, T., Hindler, J.A., Koeth, L. and Sei, K., 2018. CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests. *Journal of clinical microbiology*, 56(4).
28. EUCAST: "The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0, 2020"
29. Andrews, S., 2010. FastQC: a quality control tool for high throughput sequence data.
30. Bolger, A.M., Lohse, M. and Usadel, B., 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, 30(15), pp.2114-2120.
31. Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., Lesin, V.M., Nikolenko, S.I., Pham, S., Prjibelski, A.D. and Pyshkin, A.V., 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *Journal of computational biology*, 19(5), pp.455-477.
32. Gurevich, A., Saveliev, V., Vyahhi, N. and Tesler, G., 2013. QUAST: quality assessment tool for genome assemblies. *Bioinformatics*, 29(8), pp.1072-1075.
33. Aziz, R.K., Bartels, D., Best, A.A., DeJongh, M., Disz, T., Edwards, R.A., Formsma, K., Gerdes, S., Glass, E.M., Kubal, M. and Meyer, F., 2008. The RAST Server: rapid annotations using subsystems technology. *BMC genomics*, 9(1), pp.1-15.
34. Apweiler, R., Bairoch, A., Wu, C.H., Barker, W.C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M. and Martin, M.J., 2004. UniProt: the universal protein knowledgebase. *Nucleic acids research*, 32(suppl_1), pp.D115-D119.
35. Allaire, J., 2012. RStudio: integrated development environment for R. *Boston, MA*, 770, p.394.
36. World Health Organization, 2017. Critically important antimicrobials for human medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance due to non-human use.
37. Smith, J.R., Rybak, J.M. and Claeys, K.C., 2020. Imipenem-Cilastatin-Relebactam: A Novel β -Lactam- β -Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 40(4), pp.343-356.
38. Belbahri, L., Chenari Bouket, A., Rekik, I., Alenezi, F.N., Vallat, A., Luptakova, L., Petrovova, E., Oszako, T., Cherrad, S., Vacher, S. and Rateb, M.E., 2017. Comparative genomics of *Bacillus amyloliquefaciens* strains reveals a core genome with traits for habitat adaptation and a secondary metabolites rich accessory genome. *Frontiers in microbiology*, 8, p.1438.
39. Patel, R., Piper, K., Cockerill, F.R., Steckelberg, J.M. and Yousten, A.A., 2000. The biopesticide *Paenibacillus popilliae* has a vancomycin resistance gene cluster homologous to the enterococcal

- 405 VanA vancomycin resistance gene cluster. *Antimicrobial agents and chemotherapy*, 44(3), pp.705-
406 709.
- 407 40. Coenye, T., Mahenthiralingam, E., Henry, D., LiPuma, J.J., Laevens, S., Gillis, M., Speert, D.P. and
408 Vandamme, P., 2001. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia
409 complex including biocontrol and cystic fibrosis-related isolates. *International Journal of Systematic
410 and Evolutionary Microbiology*, 51(4), pp.1481-1490.
- 411 41. Guglierame, P., Pasca, M.R., De Rossi, E., Buroni, S., Arrigo, P., Manina, G. and Riccardi, G., 2006.
412 Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia
413 genome. *BMC microbiology*, 6(1), pp.1-14.
- 414 42. Mühlberg, E., Umstätter, F., Kleist, C., Domhan, C., Mier, W. and Uhl, P., 2020. Renaissance of
415 vancomycin: Approaches for breaking antibiotic resistance in multidrug-resistant bacteria. *Canadian
416 journal of microbiology*, 66(1), pp.11-16.
- 417 43. Luna, V.A., King, D.S., Gullledge, J., Cannons, A.C., Amuso, P.T. and Cattani, J., 2007.
418 Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and
419 Bacillus thuringiensis to 24 antimicrobials using Sensititre® automated microbroth dilution and
420 Etest® agar gradient diffusion methods. *Journal of antimicrobial chemotherapy*, 60(3), pp.555-567.
- 421 44. Turnbull, P.C., Sirianni, N.M., LeBron, C.I., Samaan, M.N., Sutton, F.N., Reyes, A.E. and Peruski,
422 L.F., 2004. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis,
423 and Bacillus mycoides from a range of clinical and environmental sources as determined by the
424 Etest. *Journal of clinical microbiology*, 42(8), pp.3626-3634.
- 425 45. Raymond, B. and Federici, B.A., 2017. In defence of Bacillus thuringiensis, the safest and most
426 successful microbial insecticide available to humanity—a response to EFSA. *FEMS microbiology
427 ecology*, 93(7), p.fix084.
- 428 46. Zhang, L., Li, X.Z. and Poole, K., 2001. SmeDEF multidrug efflux pump contributes to intrinsic
429 multidrug resistance in Stenotrophomonas maltophilia. *Antimicrobial agents and
430 chemotherapy*, 45(12), pp.3497-3503.
- 431 47. Mima, T., Kohira, N., Li, Y., Sekiya, H., Ogawa, W., Kuroda, T. and Tsuchiya, T., 2009. Gene
432 cloning and characteristics of the RND-type multidrug efflux pump MuxABC-OpmB possessing two
433 RND components in Pseudomonas aeruginosa. *Microbiology*, 155(11), pp.3509-3517.
- 434 48. Sharff, A., Fanutti, C., Shi, J., Calladine, C. and Luisi, B., 2001. The role of the TolC family in
435 protein transport and multidrug efflux. From stereochemical certainty to mechanistic
436 hypothesis. *European Journal of Biochemistry*, 268(19), pp.5011-5026.

49. Brooks, L.E., Kaze, M. and Siström, M., 2019. Where the plasmids roam: large-scale sequence analysis reveals plasmids with large host ranges. *Microbial genomics*, 5(1).
50. Vester, B., 2018. The cfr and cfr-like multiple resistance genes. *Research in microbiology*, 169(2), pp.61-66.
51. Chen, Y.T., Liao, T.L., Liu, Y.M., Lauderdale, T.L., Yan, J.J. and Tsai, S.F., 2009. Mobilization of qnrB2 and ISCR1 in plasmids. *Antimicrobial agents and chemotherapy*, 53(3), pp.1235-1237.
52. Boehme, S., Werner, G., Klare, I., Reissbrodt, R. and Witte, W., 2004. Occurrence of antibiotic-resistant enterobacteria in agricultural foodstuffs. *Molecular nutrition & food research*, 48(7), pp.522-531.
53. Iyer, R., Moussa, S.H., Tommasi, R. and Miller, A.A., 2019. Role of the *Klebsiella pneumoniae* TolC porin in antibiotic efflux. *Research in microbiology*, 170(2), pp.112-116.
54. Nishino, K., Yamada, J., Hirakawa, H., Hirata, T. and Yamaguchi, A., 2003. Roles of TolC-dependent multidrug transporters of *Escherichia coli* in resistance to β -lactams. *Antimicrobial Agents and Chemotherapy*, 47(9), pp.3030-3033.
55. Brooks, L., Kaze, M. and Siström, M., 2019. A curated, comprehensive database of plasmid sequences. *Microbiology resource announcements*, 8(1).
56. Sanchis, V., Agaisse, H., Chauvaud, J. and Lereclus, D., 1997. A recombinase-mediated system for elimination of antibiotic resistance gene markers from genetically engineered *Bacillus thuringiensis* strains. *Applied and environmental microbiology*, 63(2), pp.779-784.

Antibiotic	Biopesticide	Number replicates	MIC (µg/mL)			MIC Interpretation			Breakpoint (µg/mL)	
			Min.	Max.	Range	S%	I%	R%	S (≤)	R (≥)
Cefazolin	Bt-kurstaki-1	5	256	>256	0			100	-	-
KZ	Bt-kurstaki-2	5	256	>256	0			100	-	-
	<i>B. amyloliquefaciens</i>	5	0.125	0.125	0	100			-	-
	<i>B. subtilis</i>	5	0.064	0.094	0.03	100			-	-
Ceftazidime	Bt-kurstaki-1	5	265	>256	0			100	-	-
CAZ	Bt-kurstaki-2	5	265	>256	0			100	-	-
	<i>B. amyloliquefaciens</i>	NA							-	-
	<i>B. subtilis</i>	NA							-	-
Clindamycin	Bt-kurstaki-1	5	0.125	0.19	0.065	100			1.0	1.0
CD	Bt-kurstaki-2	5	0.19	0.19	0	100			1.0	1.0
	<i>B. amyloliquefaciens</i>	NA							-	-
	<i>B. subtilis</i>	5	0.064	0.064	0	100			1.0	1.0
Ertapenem	Bt-kurstaki-1	10	0.125	0.125	0	100			-	-
ETP	Bt-kurstaki-2	10	0.19	0.19	0	100			-	-
	<i>B. amyloliquefaciens</i>	10	0.125	0.125	0	100			-	-
	<i>B. subtilis</i>	10	0.125	0.19	0.065	100			-	-
Erythromycin	Bt-kurstaki-1	5	0.064	0.19	0.126	100			0.5	0.5
E	Bt-kurstaki-2	5	0.19	0.19	0	100			0.5	0.5
	<i>B. amyloliquefaciens</i>	5	0.125	0.125	0	100			0.5	0.5
	<i>B. subtilis</i>	5	0.002	0.25	0.248	100			0.5	0.5
Imipenem	Bt-kurstaki-1	10	1.5	1.5	0			100	0.5	0.5
IMI	Bt-kurstaki-2	10	0.094	4	3.906	80		20	0.5	0.5
	<i>B. amyloliquefaciens</i>	10	0.032	0.75	0.718	80		20	0.5	0.5
	<i>B. subtilis</i>	8	0.125	0.125	0	100			0.5	0.5
Quinupristin/ Dalfopristin	Bt-kurstaki-1	NA							-	-
QDA	Bt-kurstaki-2	NA							-	-
	<i>B. amyloliquefaciens</i>	3	3	4	1			100	-	-
	<i>B. subtilis</i>	3	3	3	0			100	-	-
Tetracycline	Bt-kurstaki-1	NA							-	-
T	Bt-kurstaki-2	NA							-	-
	<i>B. amyloliquefaciens</i>	3	4	4	0			100	-	-
	<i>B. subtilis</i>	3	3	3	0			100	-	-

% S, % susceptible; %I, % intermediate; %R, resistant; -, indicates EUCAST breakpoint references unavailable; NA, antibiotic not tested.

Antibiotic	Biopesticide	Number replicates	Zone Diameter (mm)			Interpretation			Breakpoint (mm)	
			Min.	Max.	Range	S%	I%	R%	S ($\leq$)	R ($\geq$)
Clindamycin	Bt-kurstaki-1	12	0	20	20	75		25	17	17
DA2	Bt-kurstaki-2	12	22	24	2	100			17	17
	<i>B. amyloliquefaciens</i>	12	30	31	1	100			17	17
	<i>B. subtilis</i>	12	30	30	1	100			17	17
Doxycycline	Bt-kurstaki-1	9	20	20	0	100			-	-
DO30	Bt-kurstaki-2	9	18	19	1	100			-	-
	<i>B. amyloliquefaciens</i>	9	19	21	2	100			-	-
	<i>B. subtilis</i>	9	19	20	1	100			-	-
Linezolid	Bt-kurstaki-1	12	35	36	1	100			22	22
LZD30	Bt-kurstaki-2	12	28	29	1	100			22	22
	<i>B. amyloliquefaciens</i>	12	29	30	1	100			22	22
	<i>B. subtilis</i>	12	28	31	3	100			22	22
Sulfamethoxazole/	Bt-kurstaki-1	9	20	20	0	100			-	-
Trimethoprim	Bt-kurstaki-2	9	10	22	12	67		33	-	-
SXT25	<i>B. amyloliquefaciens</i>	9	31	31	0	100			-	-
	<i>B. subtilis</i>	9	27	28	0	100			-	-
Vancomycin	Bt-kurstaki-1	12	22	22	0	100			10	10
VA30	Bt-kurstaki-2	12	19	20	0	100			10	10
	<i>B. amyloliquefaciens</i>	12	21	21	0	100			10	10
	<i>B. subtilis</i>	12	21	21	0	100			10	10

% S, % susceptible; %I, % intermediate; %R, resistant; -, indicate EUCAST breakpoint references unavailable.

Molecular Characterization of Bacillus-based Biopesticides

2a

Biopesticide	Antibiotic Resistance Gene (CARD)																			
	acrA	Bcl	BclI	Bla2	cfr(B)	clbA	cleD	hns	IsaB	mdtF	mexB	mexD	mexY	nphA	muxB	muxC	oqxA	oqxB	smeE	sulI
<i>Bt-kurstaki1</i>																				
<i>Bt-kurstaki2</i>																				
<i>B. amyloliquefaciens</i>																				
<i>B. subtilis</i>																				

2b

Biopesticide	Antibiotic Resistance Gene (Annotation)																					
	AcrA	AcrE	Amph	Bcr/CfIA	CmeA	CmeB	CmeC	ErmA	ErmB	MacA	MacB	MarA	MarB	MarR	MdfA	mdlB	tetR	TolC	vanW	vanZ	YkcC	YkdD
<i>Bt-kurstaki1</i>																						
<i>Bt-kurstaki2</i>																						
<i>B. amyloliquefaciens</i>																						
<i>B. subtilis</i>																						

Figure 2. Molecular characterization of commercial biopesticides showing the presence of antibiotic resistance genes associated with each drug class resistance phenotypes. **a.** CARD-identified ARG for each commercial biopesticide product. **b.** Annotation-identified ARG for each commercial biopesticide. Dark squares indicate gene presence.

Table 3. Antibiotic Resistance Genes Summary

Resistance Gene	Identified by	Gene Family	Resistance Mechanism	Drug Class	Reference
<i>AAC(3)-VIIa</i>	CARD	AAC(3)	Inactivation	Aminoglycosides	Lopez-Cabrera M, et al. 1989
<i>AAC(3)-Xa</i>	CARD	AAC(3)	Inactivation	Aminoglycosides	Ishikawa J, et al. 2000
<i>acrA</i>	CARD, Annotation	RND Efflux pump	Efflux	Fluoroquinolones, Glycylcyclines, Penams, Rifamycins, Cephalosporins, Tetracyclines, Triclosan	Mikoloko J, et al. 2006, Poole K. 2004
<i>AcrD</i>	CARD	RND Efflux pump	Efflux	Aminoglycosides	Rosenberg EY, et al. 2000
<i>AcrE</i>	Annotation	RND Efflux pump	Efflux	Cephalosporins, Cephamycins, Fluoroquinolones, Penams	Lau SY, et al., 2005
<i>AmpC</i>	Annotation	ACC beta-lactamase	Inactivation	Cephalosporins, Monobactams, Penams	Lister PD, et al. 2009
<i>amrA</i>	CARD	RND Efflux pump	Efflux	Aminoglycosides	Jassem AN, et al. 2014
<i>ArnC</i>	Annotation	PMR phosphoethanolamine transferase	Target alteration	Peptides	Gunn JS, et al. 1998
<i>BceAB</i>	Annotation	ABC transporters	Target alteration	Peptides	Bernard, Remi, et al. 2007
<i>Bcl</i>	CARD	Be beta-lactamase	Inactivation	Cephalosporins, Penams	Carfi A, et al. 1995
<i>BclI</i>	CARD	Be beta-lactamase	Inactivation	Cephalosporins, Penams	Carfi A, et al. 1995
<i>Bcr/CJA</i>	Annotation	MFS Efflux pump	Efflux	Tetracyclines	Kumar, S, et al., 2012
<i>Bla/Mec</i>	Annotation	Methicillin resistant PBP2	Target replacement	Penam	Joon, S., et al., 2000
<i>BlaI</i>	CARD, Annotation	Class A Bacillus anthracis beta-lactamase	Inactivation	Penam	Kim SK, et al. 2016
<i>Bla2</i>	CARD	Class A Bacillus anthracis beta-lactamase	Inactivation	Penam	Kim SK, et al. 2016
<i>bmr</i>	CARD	MFS Efflux pump	Efflux	Fluoroquinolones, Nucleosides	Klyachko KA, et al. 1997
<i>catI</i>	CARD	Chloramphenicol acetyltransferase	Inactivation	Phenicol	Elisha BG, et al. 199
<i>cfr(B)</i>	CARD	Cfr 23S ribosomal RNA methyltransferase	Target alteration	Lincosamides, Oxazolidinones, Streptogramins	Deshpande LM, et al. 2015
<i>clbA</i>	CARD	Cfr 23S ribosomal RNA methyltransferase	Target alteration	Lincosamides, Oxazolidinones, Streptogramins	Hansen LH, et al. 2012
<i>clcD</i>	CARD	Cfr 23S ribosomal RNA methyltransferase	Target alteration	Lincosamides, Oxazolidinones, Streptogramins	Hansen LH, et al. 2015
<i>CmeABC</i>	Annotation	RND Efflux pump	Efflux	Cephalosporins, Fluoroquinolones, Macrolides	Yao H, et al. 2016
<i>cmIR</i>	CARD	MFS Efflux pump	Efflux	Phenicol	Dittrich W, et al. 1991
<i>CpxA</i>	CARD, Annotation	RND Efflux pump	Efflux	Aminocoumarins, Aminoglycosides	Srinivasan VB, et al. 201
<i>CRP</i>	CARD	RND Efflux pump	Efflux	Cephalosporins, Fluoroquinolones, Macrolides	Nishino K, et al. 2008
<i>emrB</i>	CARD	MFS Efflux pump	Efflux	Fluoroquinolones	Lomovskaya O, et al. 1992
<i>ErmAB</i>	Annotation	Erm 23S ribosomal RNA methyltransferase	Target alteration	Lincosamides, Macrolides, Streptogramins	Malhotra-Kumar S, et al. 2008, Min YH, et al. 2008
<i>FoxA</i>	Annotation	Fosfomycin thiol transferase	Inactivation	Fosfomycins	Beharry Z, et al. 2005
<i>fosA5</i>	CARD	Fosfomycin thiol transferase	Inactivation	Fosfomycins	Ma Y, et al. 2015
<i>fosA6</i>	CARD	Fosfomycin thiol transferase	Inactivation	Fosfomycins	Guo Q, et al. 2016
<i>FosB</i>	CARD, Annotation	Fosfomycin thiol transferase	Inactivation	Fosfomycins	Thompson MK, et al. 2014
<i>hns</i>	CARD	RND Efflux pump	Efflux	Cephalosporins, Cephamycins, Fluoroquinolones, Macrolides, Penams, Tetracyclines	Nishino K., et al., 2004
<i>Lde</i>	Annotation	MFS Efflux pump	Efflux	Fluoroquinolones	Godreuil, et al. 2003
<i>IsaB</i>	CARD	ABC-F ATP-binding cassette protection	Target protection	Lincosamides, Macrolides, Oxazolidinones, Phenicol, Streptogramins, Tetracyclines	Malbrun B, et al. 2011
<i>MacAB-TolC</i>	Annotation	ABC efflux pump	Efflux	Macrolides	Nishino K, et al. 2005
<i>MarRAB</i>	Annotation	RND Efflux pump	Efflux	Fluoroquinolones, Glycylcyclines, Penams, Rifamycins, Cephalosporins, Tetracyclines, Triclosan	Seoane, A., et al., 1995
<i>MdfA</i>	Annotation	MFS Efflux pump	Efflux	Tetracyclines	Heng J, et al. 2015
<i>MdtB</i>	CARD, Annotation	RND Efflux pump	Efflux	Aminocoumarins	Nagakubo S, et al. 2002
<i>MdtC</i>	CARD, Annotation	RND Efflux pump	Efflux	Aminocoumarins	Nagakubo S, et al. 2002
<i>MdtF</i>	CARD	RND Efflux pump	Efflux	Fluoroquinolones, Macrolides, Penams	Nishino K., et al., 2002
<i>MdtP</i>	Annotation	MFS Efflux pump	Efflux	Nucleosides	Shimada T, et al. 2009
<i>MexB</i>	CARD	RND Efflux pump	Efflux	Aminocoumarins, Carbapenems, Cephalosporins, Cephamycins, Fluoroquinolones, Macrolides, Monobactams, Penams, Penems, Peptides, Phenicol, Sulfonamides, Tetracyclines	Welch A, et al. 2010
<i>MexDF</i>	CARD	RND Efflux pump	Efflux	Fluoroquinolones, Phenicol	Kohler T, et al. 1999
<i>MexN</i>	CARD	RND Efflux pump	Efflux	Phenicol	Mima T, et al. 2009
<i>MexY</i>	CARD	RND Efflux pump	Efflux	Aminoglycosides, Carbapenems, Cephalosporins, Cephamycins, Fluoroquinolones, Macrolides, Penams, Phenicol, Tetracyclines	Mine T, et al. 1999
<i>mphA</i>	CARD	Macrolide phosphotransferase	Inactivation	Macrolides	Chesneau O, et al. 200
<i>MuxB</i>	CARD	RND Efflux pump	Efflux	Aminocoumarins, Macrolides, Monobactams, Tetracyclines	Mima T, et al. 2009
<i>MuxC</i>	CARD	RND Efflux pump	Efflux	Aminocoumarins, Macrolides, Monobactams, Tetracyclines	Mima T, et al. 2009
<i>oqxAB</i>	CARD	RND Efflux pump	Efflux	Fluoroquinolones, Glycylcyclines, Tetracyclines	Kim HB, et al. 2009
<i>PmrJ</i>	Annotation	PMR phosphoethanolamine transferase	Target alteration	Peptides	Johnson, L. E., 2016
<i>PmrK</i>	Annotation	PMR phosphoethanolamine transferase	Target alteration	Peptides	Johnson, L. E., 2016
<i>PmrL</i>	Annotation	PMR phosphoethanolamine transferase	Target alteration	Peptides	Johnson, L. E., 2016
<i>PmrM</i>	Annotation	PMR phosphoethanolamine transferase	Target alteration	Peptides	Johnson, L. E., 2016
<i>pp-cat</i>	CARD	Chloramphenicol acetyltransferase	Inactivation	Phenicol	Kim E, et al. 1994
<i>rphB</i>	CARD	Rifampin phosphotransferase	Inactivation	Rifamycins	Pawlowski AC, et al. 2016
<i>smeE</i>	CARD	RND Efflux pump	Efflux	Fluoroquinolones, Macrolides, Phenicol, Tetracyclines	Zhang L, et al. 2001
<i>sulI</i>	CARD	Sulfonamide resistant sul	Target replacement	Sulfonamides	Doi Y, et al. 2007
<i>tet(L)</i>	CARD	MFS Efflux pump	Efflux	Tetracyclines	Roberts MC. 2005
<i>tetR</i>	Annotation	MFS Efflux pump	Efflux	Tetracyclines	Roberts MC. 2005
<i>TolC</i>	CARD, Annotation	RND, MFS and ABC efflux pumps	Efflux	Aminocoumarins, Aminoglycosides, Carbapenems, Cephalosporins, Cephamycin, Fluoroquinolones, Glycylcyclines, Penams, Phenicol, Rifamycins, Cephalosporins, Tetracyclines, Triclosan	Sharff A, et al. 2001
<i>vanRM</i>	CARD	Glycopeptide resistance	Target alteration	Glycopeptides	Xu X, et al. 2010
<i>VanW</i>	Annotation	Glycopeptide resistance	Target alteration	Glycopeptides	McKessar SJ, et al. 2000
<i>VanZ</i>	Annotation	Glycopeptide resistance	Target alteration	Glycopeptides	Courvalin P. 2005
<i>YkkCD</i>	Annotation	SMR Efflux pump	Efflux	Aminoglycosides, Phenicol, Tetracyclines	Jack DL, et al. 2000

Resistance nodulation cell division (RND), Major facilitator superfamily (MFS), ATP-binding cassette (ABC), Small multidrug resistance (SMR)

Supplemental Figure 1.

Figure S1. Selection of MIC results on Mueller Hinton agar for the *Bacillus*-based biopesticide products. **a.** *Bacillus subtilis* and cephazolin **b.** *Bacillus subtilis* and quinupristin/dalfpopristin. **c.** *Bacillus subtilis* and tetracycline. **d.** *Bacillus amyloliquefaciens* and quinupristin/dalfpopristin. **e.** Bt-kurstaki-2 and ceftazidime. **f.** Bt-kurstaki-2 and cephazolin. **g.** Bt-kurstaki-1 and erythromycin.

Supplemental Figure 2.

Figure S2. Selection of disk diffusion assay. **a.** Bt-kurstaki-1 with clindamycin, doxycycline, linezolid, sulfonamide/trimoxazole, and vancomycin. **b.** Bt-kurstaki-1 with clindamycin, doxycycline, linezolid, sulfonamide/trimoxazole, and vancomycin. Black bars indicate where measurement was taken.

Supplemental Figure 3.

Comparison of Methods for Molecular Characterization by Drug Class

Supplemental Figure 3 Comparison of two methods, annotation review and homologous gene matching using a curated database (CARD), to determine similarity for molecular characterization of resistance phenotype.

Comparison of Methods for Molecular Characterization by Drug Class

Supplemental Figure 3 Comparison of two methods, annotation review and homologous gene matching using a curated database (CARD), to determine similarity for molecular characterization of resistance phenotype.